Company / SG&A Expense
Atara Biotherapeutics, Inc. SG&A Expense History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$26.3M
FY2025
5-year range
$26.3M / $50.9M
FY2024-FY2025
Trend
-48.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$26M in FY2025.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, sg&a expense decreased 48.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score -73.54 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $26.3M | -48.4% |
| FY2024 | $50.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026